Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies

Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has shown remarkable results in regression of the size of tumors in NSCLC and has shown survival advantage. However, immune-related adverse effects are a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudry, Abdul, Chaudry, Misbat, Aslam, Jonaid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386084/
https://www.ncbi.nlm.nih.gov/pubmed/32754380
http://dx.doi.org/10.7759/cureus.8836
_version_ 1783563883066163200
author Chaudry, Abdul
Chaudry, Misbat
Aslam, Jonaid
author_facet Chaudry, Abdul
Chaudry, Misbat
Aslam, Jonaid
author_sort Chaudry, Abdul
collection PubMed
description Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has shown remarkable results in regression of the size of tumors in NSCLC and has shown survival advantage. However, immune-related adverse effects are a serious negative outcome of therapy. The number of immune-related adverse effects with pembrolizumab has increased significantly over the recent past. We present a case of type 1 diabetes mellitus and autoimmune thyroiditis with pembrolizumab treatment for NSCLC. 
format Online
Article
Text
id pubmed-7386084
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-73860842020-08-03 Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies Chaudry, Abdul Chaudry, Misbat Aslam, Jonaid Cureus Endocrinology/Diabetes/Metabolism Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has shown remarkable results in regression of the size of tumors in NSCLC and has shown survival advantage. However, immune-related adverse effects are a serious negative outcome of therapy. The number of immune-related adverse effects with pembrolizumab has increased significantly over the recent past. We present a case of type 1 diabetes mellitus and autoimmune thyroiditis with pembrolizumab treatment for NSCLC.  Cureus 2020-06-25 /pmc/articles/PMC7386084/ /pubmed/32754380 http://dx.doi.org/10.7759/cureus.8836 Text en Copyright © 2020, Chaudry et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Chaudry, Abdul
Chaudry, Misbat
Aslam, Jonaid
Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
title Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
title_full Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
title_fullStr Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
title_full_unstemmed Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
title_short Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
title_sort pembrolizumab: an immunotherapeutic agent causing endocrinopathies
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386084/
https://www.ncbi.nlm.nih.gov/pubmed/32754380
http://dx.doi.org/10.7759/cureus.8836
work_keys_str_mv AT chaudryabdul pembrolizumabanimmunotherapeuticagentcausingendocrinopathies
AT chaudrymisbat pembrolizumabanimmunotherapeuticagentcausingendocrinopathies
AT aslamjonaid pembrolizumabanimmunotherapeuticagentcausingendocrinopathies

Ejemplares similares